MREO

Mereo BioPharma Group plc MREO

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,891 of 2,925

Why it scores 8Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-7.00M

Quarter to Jun 30

Free cash flow

$-6.04M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$17.98M total
Rubric Capital Management LP
$4.86M0.0%
683 Capital Management, LLC
$3.74M-1.9%
BANK OF AMERICA CORP /DE/
$2.60M0.0%
Defilade Capital Management, L.P.
$2.40M0.0%
Newtyn Management, LLC
$953.1K-57.6%
Tejara Capital Ltd
$647.3K0.0%
UBS Group AG
$460.3K-2.9%
TWO SIGMA INVESTMENTS, LP
$419.1K+602.3%
EcoR1 Capital, LLC
$317.7K-92.5%
JANE STREET GROUP, LLC
$246.2K+453.6%
Ishara Investments LP
$244.2KNew
Wealthspire Advisors, LLC
$243.0K-3.9%
CITADEL ADVISORS LLC
$141.1KNew
Rangeley Capital, LLC
$104.6K0.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$67.8K+8.9%
MARSHALL WACE, LLP
$57.6K-73.8%
XTX Topco Ltd
$55.4K+106.6%
GROUP ONE TRADING, L.P.
$53.2K-50.1%
STATE STREET CORP
$42.8K+1.0%
NOMURA HOLDINGS INC
$33.2KNew
James J. Burns & Company, LLC
$30.3KNew
Quarry LP
$29.8KNew
GOLDMAN SACHS GROUP INC
$27.1KNew
JMN Financial LLC
$24.4KNew
BlackRock, Inc.
$22.1K-77.0%
See all 61 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/MREO

Earnings Per Share

13fpro.ai/company/MREO

Loading ratio trend…

MREO key financials by period

Reported revenue, net income and operating margin by fiscal year, from Mereo BioPharma Group plc's annual filings on SEC EDGAR.

Mereo BioPharma Group plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$500.0K$-41.9M—
FY 2023$10.0M$-29.5M—
Source: MREO filings on SEC EDGAR →

MREO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Mereo BioPharma Group plc (MREO): stock profile, AI score and financials

Mereo BioPharma Group plc (MREO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MREO at 8.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,891 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Mereo BioPharma Group plc reports net income of $-7.0M, free cash flow of $-6.0M. Top institutional holders of MREO by reported 13-F value include Rubric Capital Management, 683 Capital Management, BANK OF AMERICA, based on the most recent SEC filings. MREO trades on the Nasdaq exchange and files with the SEC under CIK 1719714. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MREO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Mereo BioPharma Group plc directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1719714 →